



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Results of Annual General Meeting held on 16 November 2016

16 November 2016 – Sydney, Australia & Auckland, New Zealand – the following voting results in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Limited held on Wednesday, 16 November 2016 are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

Resolution 1: Adoption of Remuneration Report

“That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Directors’ Report of the Company for the year ended 30 June 2016, be adopted, details of which are set out in the explanatory notes to resolution 1 in the notice of meeting.”

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY’S DISCRETION
153,912,543	1,546,405	17,082,936	7,966,182

Resolution 2: Re-election of Mr Laurie Hunter as a Director

“That Laurie Hunter, being a Director of the Company, retires by rotation in accordance with the Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 2 in the notice of meeting.”

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY’S DISCRETION
170,127,702	1,340,652	2,442,856	7,966,182

Resolution 3: Re-election of Mr Robert Willcocks as a Director

"That Robert Willcocks, being a Director of the Company, retires by rotation in accordance with the Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 3 in the notice of meeting."

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
170,964,090	514,000	2,433,120	7,966,182

Resolution 4: Approval to exempt from Listing Rule 7.1 Options issued under the Employee Share Option Plan

"That for the purposes of ASX Listing Rule 7.2 (exception 9), the issue of options under the Company's Employee Share Option Plan, on the terms and conditions set out in the explanatory notes to resolution 4 in the notice of meeting, be approved as an exception to ASX Listing Rule 7.1."

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
153,583,344	1,925,912	17,032,628	7,966,182

Resolution 5: Ratification of issue of Ordinary Shares pursuant to ASX Listing Rule 7.4

"That in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 54,607,546 fully paid ordinary shares in the capital of the Company, details of which are set out in the explanatory notes to resolution 5 in the notice of meeting."

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
135,960,774	919,678	17,934,594	857,392

Resolution 6: Ratification of issue of Ordinary Shares pursuant to ASX Listing Rule 7.4

"That in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 8,349,010 fully paid ordinary shares in the capital of the Company, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting."

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
154,432,804	913,678	3,902,281	22,279,619

Resolution 7: Board Spill Meeting

Resolution 7 was not required.

– Ends –

For further information: www.lctglobal.com

At the company: Ken Taylor Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 796000 ktaylor@lctglobal.com	Media enquires: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz
---	--

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

LCT's lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing factors to promote new central nervous system growth and repair disease induced nerve degeneration.

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases.

LCT's proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary

intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.